Vietnam Pharma Hub And Patient Access Support Service Market, By Service (Program Enrollment, Order Processing, Application Processing, Ease of Enrollment (Through Phone, Face, Portal, or App), Program Data, Treatment Navigators, Process Flows and Standard Operating Procedures, Program Literature and Scripts, Care Team Training, Systems Testing and Optimization, Reimbursement Services/Affordability Services, Clinical Educator, Coordination of Specialty Pharmacy/Dispensing, Others), By Delivery Type (Integrated Services, Standalone Services), By Region, Competition, Forecast & Opportunities, 2020-2030F

Market Overview

Vietnam Pharma Hub And Patient Access Support Service Market was valued at USD 10.25 Million in 2024 and is expected to reach USD 19.69 Million by 2030 with a CAGR of 11.45% during the forecast period. Vietnam’s pharmaceutical market is undergoing rapid growth and is positioned for sustained expansion. This trajectory is propelled by strategic public-private partnerships, robust government initiatives, and a rising prevalence of chronic and infectious diseases. Despite these advancements, the sector faces critical barriers, including stringent regulatory processes, inadequate infrastructure, and limited public awareness of healthcare solutions.

In response, domestic and international investors are channeling significant resources into the market, targeting innovation and capacity building. Companies such as Imexpharm have emerged as industry leaders, making substantial investments in research and development as well as advanced pharmaceutical manufacturing technologies to bolster their competitive edge. These targeted efforts are instrumental in driving Vietnam’s ambition to establish itself as a pharmaceutical production hub in Southeast Asia.

While the industry presents lucrative growth prospects, its success hinges on overcoming persistent challenges and aligning with international standards to unlock its full potential and achieve long-term strategic goals.

Key Market Drivers

Increasing Disease Burden and Healthcare Needs

Vietnam’s rising disease burden is a major driver of the Pharma Hub and Patient Access Support Service market. Non-communicable diseases (NCDs) now account for ~80% of all deaths, driven by urbanization, lifestyle changes, and aging. Despite progress in maternal/child health and infectious disease control, ~70–80% of people with hypertension or diabetes remain untreated, highlighting major gaps in diagnosis and long-term care.

The burden of communicable diseases has fallen sharply from 38% (morbidity) and 33% (mortality) in 1996 to a projected 18% and 6% by 2026, respectively—well below Southeast Asia averages, contributing to rising life expectancy. However, challenges persist with TB, dengue, and hepatitis B, prompting government programs such as the National Tuberculosis Program and efforts to eliminate hepatitis B by 2030, boosting demand for vaccines, antivirals, and patient support services.

Cancer incidence is increasing, with ~182,563 new cases annually. High treatment costs are accelerating the need for Patient Access Support Services, including financial assistance for targeted therapies and immunotherapies. National NCD campaigns (hypertension, diabetes) are improving detection, driving demand for pharmaceuticals and adherence programs.

Vietnam’s aging population (~12% aged 60+) and rising incomes are further increasing demand for chronic disease treatments. Growing middle-class healthcare spending is expanding access to advanced medicines and support services that reduce out-of-pocket costs, provide expert guidance, and improve treatment adherence. Together, these trends are fueling innovation, strengthening.

Growing Middle-Class Population and Healthcare Spending

Vietnam’s expanding middle class and rising healthcare spending are key drivers of the Pharma Hub and Patient Access Support Service market. Vietnam targets upper-middle-income status by 2030 and high-income by 2050, with the middle class projected to reach 26% of the population by 2026, up from 13% (~13 million people) in 2023. This demographic shift is boosting purchasing power and driving demand for preventive care, early diagnosis, branded medicines, and innovative therapies.

Healthcare expenditure continues to rise, reaching ~USD 18.5 billion in 2022 (4.6% of GDP, EIU). Alongside declining birth rates and an aging population, this is increasing demand for healthcare services. Despite improvements in public care, high out-of-pocket costs are accelerating demand for patient access services. Middle-class patients are increasingly seeking advanced treatments biologics, targeted therapies, and immunotherapies for cancer, diabetes, and cardiovascular diseases, encouraging pharma companies to localize high-cost therapies and expand support programs.

Growth of private hospitals and premium clinics is further strengthening collaboration with pharmaceutical companies through Patient Access Programs (PAPs). Rising focus on quality of life is also boosting preventive care, vaccinations, screenings, and wellness services. Expanded insurance coverage public and private combined with Medication Access Programs (MAPs) and financial assistance initiatives is improving affordability of advanced treatments.

Additionally, the tech-savvy middle class is accelerating adoption of telemedicine, online pharmacies, and app-based patient support, prompting pharma companies to integrate digital tools into access programs to improve education, adherence, and outcomes.

Rising Investments in R&D and Manufacturing Needs

Rising investments in R&D and pharmaceutical manufacturing are central to Vietnam’s Pharma Hub and Patient Access Support Service market. Under the National Strategy for the Development of the Domestic Pharmaceutical Industry through 2030 (vision 2045), Vietnam aims to meet 80% of local demand by production capacity, with domestic products contributing 70% of total market value. Government incentives including tax breaks, subsidies, and streamlined regulations are attracting both local and foreign investors to build manufacturing plants and R&D centers.

Vietnam is shifting from basic drug production to high-value pharmaceuticals, including biologics, biosimilars, vaccines, oncology treatments, and advanced formulations. Investments in international-standard facilities and R&D are supporting personalized medicine for chronic diseases such as cancer and diabetes, while partnerships between local firms, global pharma companies, and academic institutions are accelerating innovation and technology transfer.

Expanded domestic manufacturing improves patient access by lowering costs of biosimilars and generics, ensuring steady drug supply, and reducing stockouts especially in underserved areas. Multinationals such as Sanofi, Pfizer, and Takeda have invested in local production and R&D, bringing advanced expertise and strengthening Vietnam’s pharma infrastructure.

With upgraded capabilities, Vietnam is emerging as an exporter to ASEAN, Europe, and beyond, reinforcing its position as a regional pharma hub. The COVID-19 pandemic accelerated investments in domestic vaccine production for COVID-19, dengue, and influenza, improving healthcare security. Adoption of automation, AI, and IoT is further enhancing manufacturing efficiency, supply-chain reliability, and delivery of patient support services.

Download Free Sample Report

Key Market Challenges

Regulatory Barriers and Compliance Issues

Regulatory challenges represent one of the most significant barriers to growth within Vietnam's pharmaceutical market. The complexity and length of regulatory processes can impede the timely introduction of new drugs and therapies, impacting market dynamics.

Pharmaceutical companies, both local and international, often face slow approval times due to lengthy registration processes, inconsistent enforcement of regulations, and bureaucratic inefficiencies. This can result in delayed product launches and extended time-to-market. While Vietnam has made strides in aligning its regulations with international standards, discrepancies still exist. Companies often encounter challenges in obtaining EU-GMP or WHO-GMP certifications, which are crucial for both domestic and international market access. These regulatory bottlenecks hinder the entry of innovative medicines, prolong the availability of generic drugs, and slow down the overall pace of market expansion. This issue also discourages foreign investment, as companies may be wary of navigating an unpredictable regulatory landscape.

Infrastructure Limitations in Manufacturing and Distribution

The growth of the Vietnam Pharma Hub is constrained by infrastructure challenges in both the manufacturing and distribution segments. Although significant investments have been made, there remain gaps that hinder efficiency, quality assurance, and supply chain management.

A large portion of Vietnam’s pharmaceutical manufacturing facilities are still below international standards, with only a small fraction meeting EU-GMP or equivalent certifications. The lack of high-quality manufacturing infrastructure limits the production of high-value pharmaceuticals such as biologics, biosimilars, and specialized generics. The distribution network for pharmaceuticals, especially in rural or remote areas, remains underdeveloped. This results in uneven drug availability, which can create stockouts and delays in treatment for patients in need. Logistics infrastructure, including cold chain systems for temperature-sensitive medicines, is still limited in certain areas. These infrastructure limitations not only affect the quality and consistency of pharmaceutical products but also impede the ability to scale production and reach broader patient populations. Companies seeking to position Vietnam as a regional pharmaceutical hub must invest heavily in modernizing manufacturing plants and improving distribution channels, which presents both financial and logistical challenges.

Key Market Trends

Digitalization and the Integration of Technology in Healthcare Delivery

The digital transformation of Vietnam's healthcare system is rapidly accelerating, significantly impacting the pharmaceutical and patient access markets. The integration of digital tools into both pharmaceutical production and patient support services is revolutionizing how healthcare is delivered and consumed.

The widespread adoption of telemedicine, especially in the wake of the COVID-19 pandemic, is reshaping healthcare delivery. Digital platforms allow patients to consult with doctors remotely, receive prescriptions electronically, and access pharmaceutical products through online pharmacies. This shift facilitates greater patient engagement and expands access to treatments, especially in underserved regions. Pharmaceutical companies are increasingly leveraging artificial intelligence (AI) and big data to accelerate drug discovery, personalize treatment regimens, and improve patient outcomes. AI-driven insights allow for faster identification of drug efficacy, while big data analytics enable companies to anticipate healthcare needs and improve the efficiency of patient access programs. Digital tools for remote monitoring of chronic diseases and medication adherence are becoming more prevalent. These tools help patients stay on track with their treatment plans, enhancing medication adherence and improving health outcomes, particularly for chronic conditions such as diabetes and cardiovascular diseases.

Focus on Personalized Medicine and Tailored Patient Support

The growing emphasis on personalized medicine is driving the development of treatments that are specifically tailored to an individual’s genetic profile, lifestyle, and health conditions. This trend is transforming the pharmaceutical market in Vietnam, creating demand for more specialized drugs and patient-centric support services.

The use of genetic testing to determine the most effective treatments for patients is gaining momentum. As demand for precision medicine grows, pharmaceutical companies are developing biologics and targeted therapies to offer highly personalized treatment options. This trend is shifting the market from one-size-fits-all solutions to tailored drug regimens that can be more effective and cause fewer side effects. As treatments become more personalized, so too must the patient support services. This involves creating bespoke access programs that consider a patient’s unique needs, including financial assistance, adherence support, and educational resources. Personalized patient support is becoming increasingly important as patients demand more tailored solutions to help manage complex conditions. With the increased use of genomic data, pharmaceutical companies can design more effective treatment protocols, enhancing patient outcomes and reducing healthcare costs by focusing on the most effective treatment for individual patients.

Segmental Insights

Service Insights

In 2024, the Program Enrollment segment dominated Vietnam’s Pharma Hub and Patient Access Support Service market. These services connect eligible patients to Financial Assistance Programs (FAPs), reducing or eliminating out-of-pocket costs and enabling access to subsidized or free medications significantly improving treatment adherence and outcomes. Pharma companies typically run these programs with local health authorities or nonprofits, expanding product reach while ensuring patients don’t forgo treatment due to financial barriers.

Program Enrollment also solves a key operational challenge by streamlining patient access to assistance programs, especially in Vietnam’s uneven urban–rural healthcare landscape. Digitalized enrollment covering patient data collection, eligibility verification, and database registration reduces administrative burden and speeds up medication access. Mobile apps and online portals further simplify registration by providing real-time information on available programs and eligibility, improving accessibility even for patients with limited digital literacy. These efficiencies are expected to continue driving growth of this segment.

Download Free Sample Report

Regional Insights

Southern Vietnam emerged as the dominant in the Vietnam's Pharma Hub and Patient Access Support Service Market in 2024, holding the largest market share in terms of value. The Southern region, with Ho Chi Minh City as the economic and pharmaceutical hub, plays a dominant role in Vietnam’s pharmaceutical sector. The region benefits from robust healthcare infrastructure, better access to international markets, and stronger collaboration between the government, pharmaceutical companies, and healthcare providers.

Ho Chi Minh City is Vietnam's economic powerhouse, home to the highest concentration of pharmaceutical companies, multinational drug manufacturers, research institutions, and healthcare providers. The city attracts both local and foreign investments due to its strong industrial base and connectivity to global trade networks. The region also hosts many regional headquarters and production facilities for global pharmaceutical companies, enhancing the presence of multinational players in the local market and supporting the overall growth of the Pharma Hub. The Southern region has the most advanced healthcare infrastructure in Vietnam, including hospitals, research centers, and diagnostic laboratories. Many top-tier medical institutions are located in Ho Chi Minh City, providing the foundation for sophisticated patient care services, including patient access programs for high-cost medications and advanced therapies. The well-established distribution channels for pharmaceutical products in the South ensure efficient and widespread availability of medicines, which is essential for patient access services. The region’s robust logistics capabilities enable companies to scale their operations and deliver items across the country promptly.

Recent Developments

• In January 2026, Lotus Pharmaceutical announced progress on its acquisition of the Vietnam drug portfolio, covering trademarks, market authorisations, and the assignment of manufacturing/supply agreements for five products in Vietnam, with sales expected to commence in Q1 2026.
• In December 2025, Takeda highlighted the launch of an affordability-based Patient Assistance Program in Vietnam to help eligible patients access newer medicines and targeted therapies.
• In October 2025, Roche Pharma Vietnam and the Cancer Patient Support Fund – Bright Future Fund launched the 2025 “Joining Hands for Her” campaign as a patient-support initiative tied to access and awareness.
• In May 2025, Buymed emphasized its tech-enabled distribution model (including digital tracking and direct manufacturer-to-pharmacy distribution) as part of the STADA Pymepharco partnership, aimed at improving access to medicines in remote areas.
• In May 2025, STADA Pymepharco and Buymed formalized a strategic agreement in Ho Chi Minh City to expand digital pharma access across Vietnam by combining STADA Pymepharco’s manufacturing portfolio with Buymed’s digital distribution platform (thuocsi.vn) and pharmacy/provider network.
• In October 2024, A draft of the revised Pharmacy Law is set to be presented during the current National Assembly session, aimed at improving public access to new medicines. Over the past decade, Vietnam has introduced only 9% of new medicines, a significantly lower rate than other Asia-Pacific nations, which have introduced 20%. This reform seeks to address this gap and streamline the regulatory process, enhancing the availability of innovative treatments for the Vietnamese population.
• In November 2024, Singapore-listed Thomson Medical Group (TMG) has completed its largest healthcare acquisition in Southeast Asia since 2020, acquiring Vietnam’s leading private healthcare provider, FV Hospital, for approximately US$381.4 million (S$517 million). This acquisition represents a strategic expansion for TMG into one of the region’s most dynamic economies, establishing a significant foothold in Vietnam, which boasts a population of 98 million.

Key Market Players

• MCKESSON CORPORATION
• Inizio
• Cardinal Health
• Envoy Health, Inc.
• EVERSANA

Report Scope:

In this report, the Vietnam Pharma Hub And Patient Access Support Service Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Vietnam Pharma Hub And Patient Access Support Service Market, By Service:

o   Program Enrollment

o   Order Processing

o   Application Processing

o   Ease of Enrollment (Through Phone, Face, Portal, or App)

o   Program Data

o   Treatment Navigators

o   Process Flows and Standard Operating Procedures

o   Program Literature and Scripts

o   Care Team Training

o   Systems Testing and Optimization

o   Reimbursement Services/Affordability Services

o   Clinical Educator

o   Coordination of Specialty Pharmacy/Dispensing

o   Others

• Vietnam Pharma Hub And Patient Access Support Service Market, By Delivery Type:

o   Integrated Services

o   Standalone Services

• Vietnam Pharma Hub And Patient Access Support Service Market, By Region:

o   Northern Vietnam

o   Central Vietnam

o   Southern Vietnam

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Vietnam Pharma Hub And Patient Access Support Service Market.

Available Customizations:

 Vietnam Pharma Hub And Patient Access Support Service market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).